Clinical trial
Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.
NCT03843905 is registered in ClinicalTrials.gov with University Hospital, Clermont-Ferrand as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- November 15, 2018
- Completion date
- November 15, 2021
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal neoplasms, metabolic syndrome, microbiota, prognosis, sarcopenia